Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/23/2026 | $10.00 | Mkt Outperform | Citizens |
| 7/2/2024 | $11.00 | Overweight | Cantor Fitzgerald |
| 3/7/2024 | $12.00 | Buy | Lake Street |
| 10/27/2023 | $12.00 | Buy | Craig Hallum |
| 10/13/2022 | $7.00 | Buy | Mizuho |
| 9/14/2021 | $20.00 → $8.50 | Buy | HC Wainwright & Co. |
| 7/26/2021 | $23.00 | Outperform | Northland Capital |
Citizens initiated coverage of MiMedx Group with a rating of Mkt Outperform and set a new price target of $10.00
Cantor Fitzgerald initiated coverage of MiMedx Group with a rating of Overweight and set a new price target of $11.00
Lake Street initiated coverage of MiMedx Group with a rating of Buy and set a new price target of $12.00
4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
Issued on behalf of Conexeu Sciences Inc.A newly listed regenerative-tissue company has put its lead breast-reconstruction matrix on the bench at one of the world's largest bioprinting institutes. For investors tracking the space, the partner it chose may matter more than anything it has said.Equity Insider Market CommentaryTAMPA, Fla., June 2, 2026 /CNW/ -- For more than half a century, the answer to lost tissue has been to manufacture a substitute and put it where the tissue used to be. Replace, don't restore. That logic built the modern implant industry, and it works — up to a point. But it leaves a gap, and the gap shows up in the numbers: roughly two-thirds of the more than 100,000 wome
MARIETTA, Ga., May 21, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that members of its senior management will participate in the Craig-Hallum 23rd Annual Institutional Investor Conference on Thursday, May 28, 2026 in Minneapolis, MN. Investors interested in meeting with senior management may contact their Craig-Hallum representative. About MIMEDXMIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade and a half of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare.
Flowable Biomimetic Matrix Adds Self-Assembling Peptide Technology to Company's Portfolio G4Derm Plus Added to Premier and Vizient GPO Agreements MARIETTA, Ga., May 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the commercial launch of G4Derm Plus, with initial sales of the product already delivered to customers nationwide. MIMEDX recently acquired exclusive distribution rights for G4Derm Plus in the United States, adding the innovative peptide matrix to its broadening portfolio of solutions for Surgical markets. "This launch showcases our efforts to leverage our sizable commercial reach to expand solutions available to clinici
DEFA14A - MIMEDX GROUP, INC. (0001376339) (Filer)
8-K - MIMEDX GROUP, INC. (0001376339) (Filer)
DEF 14A - MIMEDX GROUP, INC. (0001376339) (Filer)
4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company's principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO. Mr. Barry succeeds Remi Barbier, the Company's Chairman, President and CEO, who resigned from the Company and the Board. Mr. Barbier will remain employed by the Company until September 13, 2024 in a
MARIETTA, Ga., June 26, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the appointment of Kim Moller to Chief Commercial Officer. Ms. Moller has been serving as the Company's Senior Vice President, Sales since August 2020. "I am pleased to announce this well-deserved promotion of Kim to Chief Commercial Officer for MIMEDX," stated Joseph H. Capper, MIMEDX Chief Executive Officer. "Under Kim's leadership as SVP of Sales for the past four years, the MIMEDX commercial organization has navigated significant change and has been transformed into the high-performing team we have today. As we continue to work our way through a period of swe
MARIETTA, Ga., March 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the appointments of Tiffany Olson and Dorothy Puhy to its Board of Directors, effective as of March 1, 2024. Ms. Olson and Ms. Puhy each bring extensive and relevant experience across the healthcare industry, with demonstrated records of executive leadership, strategic counsel and shareholder value creation. In connection with these appointments, the Board of Directors unanimously agreed to expand its size to eleven directors. M. Kathleen Behrens, Chair of the Board at MIMEDX, stated, "On behalf of the entire Board of Directors, we are honored to welcome these a
SC 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)
SC 13G - MIMEDX GROUP, INC. (0001376339) (Subject)
SC 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)
Reports First Quarter Net Sales of $59 Million Revises 2026 Net Sales and Adjusted EBITDA Expectations Management to Host Conference Call Today, April 29, 2026, at 4:30 PM ET MARIETTA, Ga., April 29, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the first quarter 2026. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "The first quarter of 2026 was adversely impacted as new Medicare reimbursement policies in the advanced wound care space went into effect at the start of the year and led to significant confusion across the industry in nearly every care setting. Additio
MARIETTA, Ga., April 22, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the first quarter ended March 31, 2026 after the market close on Wednesday, April 29, 2026. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13759618 A replay of the webcast will be available for approximately 30 days on the Company's
MARIETTA, Ga., April 16, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced a series of cost reduction initiatives intended to prioritize growth opportunities, streamline operations and significantly reduce operating expenses. As part of these changes, the position of Chief Operating Officer, held by Ricci Whitlow, has been eliminated. "On behalf of the Board and management team, I want to thank Ricci for her innumerable contributions to MIMEDX and her exceptional leadership in helping to build and scale our operations," stated Joseph H. Capper, MIMEDX Chief Executive Officer. "Ricci joined the Company at a pivotal time in the organizatio